The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...

There are also several side effects with approved IPF drugs, including commonly reported symptoms such as diarrhoea, nausea, and stomach pain, which affect around two thirds of patients taking Ofev.

This drug candidate comes at an opportune time as Sörensen said in the release that there is a need for a new treatment for IPF. Currently, patients with this disease only have two FDA-approved ...

Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with ...